Generian Pharmaceuticals, Inc
Generian Pharmaceuticals is a preclinical biotechnology company focused on developing novel, orally available small molecule therapeutics for diseases with high unmet need, especially in areas dominated by biologics. They aim to address the shortcomings of biologics by increasing convenience, access, and reducing costs through small molecule drugs. The company leverages a proprietary platform to advance a pipeline of first-in-class drug candidates that modulate target protein structure and function, with programs for both validated and novel targets, including collaborations with Astellas and Mitobridge.
Industries
Nr. of Employees
small (1-50)
Generian Pharmaceuticals, Inc
Products
Preclinical small-molecule pipeline (FcRn inhibitors; transcription factor stabilizers/degraders)
A pipeline of orally bioavailable small-molecule programs including functional inhibitors of FcRn and programs that stabilize or degrade transcription factors; candidates are advanced through preclinical assays using cell-based binding screens and high-content phenotypic validation.
Preclinical small-molecule pipeline (FcRn inhibitors; transcription factor stabilizers/degraders)
A pipeline of orally bioavailable small-molecule programs including functional inhibitors of FcRn and programs that stabilize or degrade transcription factors; candidates are advanced through preclinical assays using cell-based binding screens and high-content phenotypic validation.
Services
Research collaboration and licensing
Joint research and preclinical development agreements to discover novel small molecules for difficult-to-drug targets; collaborators take responsibility for clinical development, manufacturing, and commercialization under license terms.
Research collaboration and licensing
Joint research and preclinical development agreements to discover novel small molecules for difficult-to-drug targets; collaborators take responsibility for clinical development, manufacturing, and commercialization under license terms.
Expertise Areas
- Small-molecule drug discovery
- Targeted protein modulation (stabilization, degradation, activation)
- Cell-based screening and phenotypic assays
- Preclinical candidate progression and lead optimization
Key Technologies
- Cell-based screening in native cellular context
- High-content phenotypic screening
- Small-molecule hit discovery
- Target engagement and functional cellular assays